Ceftriaxone injection for bacterial infections

Ceftriaxone for injection is a broad-spectrum cephalosporin antibiotic given by intravenous or intramuscular injection. It is used to treat various bacterial infections caused by susceptible organisms and to prevent infections during certain surgical procedures.

Ceftriaxone for injection is indicated to treat infections caused by susceptible bacteria, including:

• Lower respiratory tract infections
• Acute bacterial otitis media
• Skin and skin structure infections
• Complicated and uncomplicated urinary tract infections
• Uncomplicated gonorrhea (cervical/urethral, rectal, and pharyngeal)
• Pelvic inflammatory disease (with additional treatment for Chlamydia trachomatis if suspected)
• Bacterial septicemia
• Bone and joint infections
• Intra-abdominal infections
• Meningitis caused by certain bacteria
• Surgical prophylaxis to reduce postoperative infections in contaminated or potentially contaminated procedures, particularly in high-risk patients

Use should be limited to infections proven or strongly suspected to be caused by susceptible bacteria.

Ceftriaxone sodium

Ceftriaxone kills bacteria by inhibiting their ability to form cell walls, which are essential for their survival. It remains effective in the presence of some bacterial enzymes called beta-lactamases that normally break down similar antibiotics.

Ceftriaxone is administered by intramuscular or intravenous injection. Dosage varies depending on the infection and patient population but generally ranges from 0.5 to 2 grams given once or twice daily. For surgical prophylaxis, a single 1 gram dose given preoperatively is recommended.

The drug is fully absorbed following intramuscular injection, with peak blood levels occurring 2 to 3 hours post-dose. Repeated doses can cause moderate drug accumulation.

Dosing adjustments are not required for elderly patients or those with renal or hepatic impairment when dosed up to 2 grams per day. However, ceftriaxone is not removed by hemodialysis and clearance may be reduced in some dialysis patients.

Consult specific product labeling for exact dosing regimens tailored to the infection treated.

• Known hypersensitivity to ceftriaxone, any cephalosporin, or any excipients.
• Premature neonates up to a post-menstrual age of 41 weeks.
• Hyperbilirubinemic neonates.
• Neonates (≤28 days) requiring or expected to require calcium-containing intravenous solutions.
• Intravenous ceftriaxone solutions containing lidocaine.

• Serious hypersensitivity and anaphylactic reactions can occur, especially in patients with prior allergy to penicillins or other beta-lactams. Therapy must be stopped immediately if severe allergic reactions develop.
• Do not use ceftriaxone with calcium-containing intravenous solutions in neonates (≤28 days), due to risk of fatal precipitates causing lung and kidney damage.
• In premature neonates up to 41 weeks post-menstrual age and neonates with hyperbilirubinemia, ceftriaxone is contraindicated because it can displace bilirubin from albumin and increase the risk of bilirubin brain toxicity.
• Calcium-containing diluents like Ringer’s or Hartmann’s solution must not be used for reconstituting or diluting ceftriaxone for injection.
• Intravenous ceftriaxone solutions containing lidocaine are contraindicated.

The label does not provide detailed frequency data, but hypersensitivity reactions such as rash, itching, and anaphylaxis are serious potential side effects. Other side effects are not specifically enumerated in the supplied text.

• Calcium-containing solutions react with ceftriaxone, leading to precipitation; avoid co-administration especially in neonates.
• Chloramphenicol may antagonize ceftriaxone's effects.
• Co-administration with probenecid does not alter ceftriaxone elimination.

The label does not provide specific information on use during pregnancy or lactation.